Eribulin in HER2 Negative Metastatic BrCa
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Erica Mayer, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Eastern Maine Medical Center
Bangor, Maine, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute at Faulkner Hospital
Boston, Massachusetts, United States
- Df/bwcc at Milford Regional Cancer Center
Milford, Massachusetts, United States
- South Shore Hospital
Weymouth, Massachusetts, United States
- Dana-Farber/new Hampshire Oncology-Hematology
Londonderry, New Hampshire, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2013
- Primary completion
- 31 May 2016
- Completion
- 31 May 2016
- Last update posted
- 6 Nov 2024
- Registered enrollment
- 83
- Registry id
- NCT01827787
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.